Coverage for weight loss alone (without diabetes) remains more limited and typically requires private insurance or out-of-pocket payment
But this power comes with a well-known initiation phase
Most patients keep the same weekly dose they tolerated previously, with B12 added
Your digestive tract gradually adapts to this new signaling pattern
During the opening lecture at the International Conference on Advanced Technologies & Treatments for Diabetes, Melanie Davies, CBE, MB, ChB, MD, FRCP, FRCGP, professor of diabetes medicine at the University of Leicester and an honorary consultant diabetologist at the University Hospitals of Leicester NHS Trust, reviewed how GLP-1 receptor agonists such as semaglutide (Ozempic/Wegovy, Novo Nordisk) have changed the way providers approach the treatment of type 2 diabetes and obesity and discussed some of the medications that combine GLP-1 with other molecules